MX2023005840A - Terapias de inhibicion de ezh2 para el tratamiento de canceres de prostata con mutacion del receptor de androgenos. - Google Patents
Terapias de inhibicion de ezh2 para el tratamiento de canceres de prostata con mutacion del receptor de androgenos.Info
- Publication number
- MX2023005840A MX2023005840A MX2023005840A MX2023005840A MX2023005840A MX 2023005840 A MX2023005840 A MX 2023005840A MX 2023005840 A MX2023005840 A MX 2023005840A MX 2023005840 A MX2023005840 A MX 2023005840A MX 2023005840 A MX2023005840 A MX 2023005840A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen receptor
- treatment
- prostate cancers
- ezh2 inhibition
- inhibition therapies
- Prior art date
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- CAAWBLRXQXMGHV-UHFFFAOYSA-N 7-chloro-2-[4-(3-methoxyazetidin-1-yl)cyclohexyl]-2,4-dimethyl-N-[(6-methyl-4-methylsulfanyl-2-oxo-1H-pyridin-3-yl)methyl]-1,3-benzodioxole-5-carboxamide Chemical compound ClC1=CC(=C(C2=C1OC(O2)(C)C1CCC(CC1)N1CC(C1)OC)C)C(=O)NCC=1C(NC(=CC=1SC)C)=O CAAWBLRXQXMGHV-UHFFFAOYSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004671 enzalutamide Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar el cáncer de próstata que tiene al menos una mutación AR patógena usando 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil -N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)ben zo[d][1,3]dioxol-5-carboxamida, o una sal del mismo farmacéuticamente aceptable, solo o en combinación con una cantidad terapéuticamente efectiva de un inhibidor de la señalización del receptor de andrógenos (ARSI) tal como enzalutamida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115165P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/059847 WO2022109106A1 (en) | 2020-11-18 | 2021-11-18 | Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005840A true MX2023005840A (es) | 2023-06-02 |
Family
ID=79024100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005840A MX2023005840A (es) | 2020-11-18 | 2021-11-18 | Terapias de inhibicion de ezh2 para el tratamiento de canceres de prostata con mutacion del receptor de androgenos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230414593A1 (es) |
| EP (1) | EP4247371A1 (es) |
| JP (1) | JP2023549564A (es) |
| KR (1) | KR20230110527A (es) |
| CN (1) | CN116600804A (es) |
| AU (1) | AU2021382606A1 (es) |
| CA (1) | CA3199421A1 (es) |
| CL (1) | CL2023001408A1 (es) |
| IL (1) | IL303025A (es) |
| MX (1) | MX2023005840A (es) |
| WO (1) | WO2022109106A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092490A1 (ru) * | 2018-04-18 | 2020-12-23 | Констеллейшен Фармасьютикалс, Инк. | Модуляторы метилмодифицирующих ферментов, композиции и их применения |
-
2021
- 2021-11-18 CA CA3199421A patent/CA3199421A1/en active Pending
- 2021-11-18 MX MX2023005840A patent/MX2023005840A/es unknown
- 2021-11-18 AU AU2021382606A patent/AU2021382606A1/en active Pending
- 2021-11-18 KR KR1020237017778A patent/KR20230110527A/ko unknown
- 2021-11-18 CN CN202180077565.8A patent/CN116600804A/zh active Pending
- 2021-11-18 WO PCT/US2021/059847 patent/WO2022109106A1/en active Application Filing
- 2021-11-18 EP EP21827282.1A patent/EP4247371A1/en active Pending
- 2021-11-18 US US18/037,120 patent/US20230414593A1/en active Pending
- 2021-11-18 JP JP2023529941A patent/JP2023549564A/ja active Pending
- 2021-11-18 IL IL303025A patent/IL303025A/en unknown
-
2023
- 2023-05-16 CL CL2023001408A patent/CL2023001408A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022109106A1 (en) | 2022-05-27 |
| EP4247371A1 (en) | 2023-09-27 |
| CL2023001408A1 (es) | 2024-01-12 |
| US20230414593A1 (en) | 2023-12-28 |
| CN116600804A (zh) | 2023-08-15 |
| AU2021382606A1 (en) | 2023-06-22 |
| IL303025A (en) | 2023-07-01 |
| JP2023549564A (ja) | 2023-11-27 |
| CA3199421A1 (en) | 2022-05-27 |
| KR20230110527A (ko) | 2023-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
| MX2022004656A (es) | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. | |
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
| MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
| MX2021005700A (es) | Inhibidores de kras g12c y metodos de uso de los mismos. | |
| MX2020011582A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| MX2020011250A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| MX2022010082A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2022000933A (es) | Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer. | |
| WO2016106331A8 (en) | Mutant idh1 inhibitors useful for treating cancer | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| PH12020551851A1 (en) | Treatment of cancers having driving oncogenic mutations | |
| MX2023011853A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. | |
| MX2021002805A (es) | Terapias de combinacion. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| WO2020092792A3 (en) | Method of enhancing immune-based therapy | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. |